CHAD KOYANAGI: Open Payments
NPI 1770536088 · HONOLULU, HI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,515 in 21 payments from 9 companies in 2025. Trend: 2023 $1,436 · 2024 $2,235 · 2025 $1,515
Food & beverage: $1,515
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 4 | $345 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $258 |
| Janssen Scientific Affairs, LLC | 2 | $198 |
| Teva Pharmaceuticals USA, Inc. | 5 | $195 |
| Otsuka America Pharmaceutical, Inc. | 2 | $145 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $126 |
| Gilead Sciences, Inc. | 1 | $125 |
| E.R. Squibb & Sons, L.L.C. | 2 | $95 |
| ABBVIE INC. | 1 | $27 |
Products named: INVEGA SUSTENNA, CAPLYTA, Yeztugo, AUSTEDO XR, ABILIFY ASIMTUFII, SPRAVATO, ABILIFY MAINTENA, COBENFY.
Industry payments across HI — which companies pay providers there.
